After Godzilla’s success, another huge franchise is coming to Fortnite, as the Battle Royale will release Avatar skins for Valentine’s Day.

We haven’t seen the last of this Fortnite skin, as it makes a return for yet another season in Chapter 6, Season 2.

Whilst it remains unclear, what, exactly, the collaboration will be, noted Fortnite leaker HypeX said the status change likely comes because "they probably made a lot of progress and moved into ...

Fortnite just launched Season 2 of Fortnite OG. This continues the mode's support now that it's a permanent feature in the game. Now, you can jump into a recreation of Chapter 2's map, with Tilted ...

The Fortnite quests have now reached their peak for the time being, with the final set of Weekly quests added as the Demon Hunters season begins to wind down. This means you have a little over a ...

Feb. 6, 2025 — A team of international researchers has developed an innovative approach to uncover the secrets of dark matter in the cosmos. They are searching for dark matter using atomic ...

Fortnite OG wowed players when it first returned, offering up retooled versions of various classic seasons, which changed each week. It proved to be a massive hit, with player counts absolutely ...

Who are the latest Fortnite NPCs? Fortnite NPC locations change with every new season, much like everything else, with more added throughout the season as well. This makes it difficult to keep ...

What does the latest Fortnite map look like? It’s not a new concept for Fortnite, but the island has taken on a Japanese feel again with the latest season: Hunters. This time, iconic characters ...

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.